ALK-Abelló A/S (LON:0OIR)

Market Cap	5.38B +41.0%
Revenue (ttm)	737.29M +14.0%
Net Income	139.82M +46.9%
EPS	0.63 +46.7%
Shares Out	n/a
PE Ratio	38.50
Forward PE	32.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,329
Average Volume	37,524
Open	212.30
Previous Close	215.40
Day's Range	208.60 - 213.00
52-Week Range	131.30 - 237.60
Beta	0.60
RSI	41.14
Earnings Date	Feb 20, 2026

About ALK-Abelló

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1923
• Employees: 2,613
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0OIR

Financial Performance

In 2025, ALK-Abelló's revenue was 6.31 billion, an increase of 14.00% compared to the previous year's 5.54 billion. Earnings were 1.20 billion, an increase of 46.87%.

Financial numbers in DKK